Fig. 3: Overall survival. | Nature Communications

Fig. 3: Overall survival.

From: Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Fig. 3

Reported for A, the Chinese cohort overall population and B, patients with PIK3CA/AKT1/PTEN-altered tumors. The hazard ratio of the capivasertib–fulvestrant (purple) and placebo–fulvestrant (blue) curves was estimated with the use of the Cox proportional hazards model, with stratification according to the previous use of a CDK4/6 inhibitor (yes or no) in the overall population. Results for the population of patients with PIK3CA/AKT1/PTEN-altered tumors are not presented due to an insufficient number of events (<20 across treatment groups). A sufficient number of deaths for a formal analysis of overall survival had not occurred by the data cutoff date (8 May 2023). Tick marks indicate censored data. A 0.01% alpha penalty was assigned to the overall survival analyses of no detriment (i.e. with the hazard ratio not favoring the placebo–fulvestrant group). AKT1 Akt serine/threonine kinase 1, CDK4/6 cyclin-dependent kinase 4/6, CI confidence interval, NA non-applicable, NC not calculated, OS overall survival, PIK3CA catalytic subunit alpha of phosphatidylinositol-3-kinase, PFS progression-free survival, PTEN phosphatase and tensin homolog.

Back to article page